Proove Biosciences Continues Its Research Leadership in the Genetics of Pain Medicine at The American Academy of Pain Management’s 24th Annual Meeting

Proove will be exhibiting and participating at the AAPM’s Annual Meeting, and build upon the interest generated from the several industry events already attended this year.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
We are pleased to again have our research selected by experts in the field to be presented at another industry leading conference.

Irvine, CA (PRWEB) September 25, 2013

Proove Biosciences Inc. (http://www.proovebio.com), the leading personalized pain medicine laboratory, announces that they will again be presenting research on the genetics of pain medicine at a major scientific meeting this year. This weekend, Proove will present preliminary findings from a clinical study during the poster session and will exhibit at the American Academy of Pain Management’s 24th Annual Clinical Meeting at the JW Marriott Orlando, Orlando, Florida. The event will be held from September 26th to September 29nd. Proove will be presenting research on the clinical and economic outcomes of using the Proove Narcotic Risk Genetics Test in the treatment and management of pain.

The American Academy of Pain Management is the one of largest pain management organizations in the nation and uniquely embraces an integrative model of care, which includes bringing together all appropriate therapeutic approaches and a team of clinicians to reduce pain and achieve optimal health and healing. The AAPM also offers continuing education, publications, and advocacy.

Proove Biosciences CEO, Brian Meshkin, states, “We are pleased to again have our research selected by experts in the field to be presented at another industry leading conference. The AAPM’s Annual Clinical Meeting brings together over 1200 clinicians across all disciplines in pain management, and offers Proove another opportunity to help educate about the importance of using genetic testing in pain management.”

Proove will be exhibiting at the scientific meeting to help educate clinicians about its proprietary genetic testing to personalize pain medicine and will be presenting some additional preliminary data at the poster session on the R.A.C.E.R. Study,”Retrospective Analysis of the Clinical and Economic Results (R.A.C.E.R.) of Genotyping Chronic Pain Patients to Guide Medical Detoxification of Prescription Opioid Analgesic Abuse (RxO): Two-Year Study.” In this study, principal investigator, Dr. Gregory Smith, utilized an integrated, team-based medical approach to detoxification. In the R.A.C.E.R. Study, Proove investigators conducted a pilot study to explore how genotyping could correlate or associate with outcomes of medical detoxification, and whether genotype could predict outcomes. At this meeting, researchers will prevent preliminary findings that suggest the Proove Narcotic Risk test may assist clinicians in improving outcomes of medical detoxification in patients abusing prescription narcotic pain medication.

About Proove Biosciences
Proove Biosciences is the leading Personalized Pain Medicine laboratory that provides proprietary genetic testing services to help physicians improve outcomes for patients and contain costs for insurers. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve pain medicine selection, dosing, and evaluation of medications they prescribe. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proovebio.com or call toll free 855-PROOVE-BIO (855-776-6832).


Contact